Metformin Shown to Prevent Long COVID Across Risk Groups

Groundbreaking research from the University of Minnesota Medical School suggests metformin can significantly reduce the risk of developing Long COVID.

Jan. 29, 2026 at 10:15pm

Got story updates? Submit your updates here. ›

In a potential game-changer for post-COVID care, new research from the University of Minnesota Medical School indicates that metformin, a widely used diabetes medication, can significantly reduce the risk of developing Long COVID. The findings, based on multiple randomized trials, reveal that for every 50 people with acute COVID-19 treated with 14 days of metformin, one case of Long COVID could be prevented.

Why it matters

This research offers a proactive approach to addressing the debilitating effects of Long COVID, which has impacted millions worldwide. Metformin's ability to decrease viral load and minimize the inflammatory response triggered by the virus suggests it could be a valuable addition to comprehensive COVID-19 treatment plans.

The details

The University of Minnesota team's review of four studies shows that metformin can benefit individuals with varying risk levels, including those with pre-existing conditions and previous COVID-19 infections. Importantly, the research found metformin to be safe, with no reported instances of low blood sugar or serious side effects during the acute infection phase.

  • The research findings were published on January 29, 2026.

The players

University of Minnesota Medical School

The institution where the groundbreaking research on metformin's potential to prevent Long COVID was conducted.

Dr. Carolyn Bramante

The lead researcher and assistant professor at the University of Minnesota Medical School who led the study.

Got photos? Submit your photos here. ›

What they’re saying

“Metformin has emerged as the first intervention to prevent Long COVID in low to high risk adults. This robust evidence suggests that starting metformin at the onset of a COVID-19 infection could dramatically reduce the long-term health consequences for a large portion of the population.”

— Dr. Carolyn Bramante, Lead Researcher and Assistant Professor, University of Minnesota Medical School (Clinical Infectious Diseases)

What’s next

Larger, more diverse clinical trials will be needed to confirm these findings and identify specific patient populations who benefit most from metformin. Research will also focus on determining the safety and efficacy of metformin in children with COVID-19, as well as exploring whether metformin can alleviate existing Long COVID symptoms.

The takeaway

This research on metformin's potential to prevent Long COVID offers a promising new approach to addressing the long-term health consequences of the pandemic. If confirmed in larger trials, metformin could become a valuable tool in the fight against the debilitating effects of Long COVID, potentially reducing the burden on healthcare systems and improving public health outcomes.